Analysts expect Gyre Therapeutics, Inc. to report revenue of 29.84 M for Q3 26, against a range of 28.69 M to 30.98 M. The most recent reported quarter, Q2 26, came in at 29.11 M, a 6.2% beat against the 27.42 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 25.49 M | 27.87 M | 22.06 M | 26.77 M | 30.56 M | 37.20 M | 22.52 M | 29.11 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | - | 25.28 M | 30.12 M | 34.02 M | 36.06 M | 38.02 M | 32.42 M | 28.78 M | 30.98 M | 32.69 M | 29.47 M | 35.39 M | 41.17 M | 45.11 M | 73.78 M | 109.42 M | ||||||||||
| Low Estimate | - | 23.48 M | 24.92 M | 29.72 M | 33.96 M | 34.89 M | 28.87 M | 26.06 M | 28.69 M | 29.83 M | 24.78 M | 32.01 M | 37.29 M | 37.98 M | 68.22 M | 96.81 M | ||||||||||
| Consensus Estimate | - | 24.38 M | 27.52 M | 31.87 M | 35.01 M | 36.45 M | 30.65 M | 27.42 M | 29.84 M | 31.26 M | 27.13 M | 33.70 M | 39.23 M | 41.54 M | 71.00 M | 103.12 M |
Analysts expect Gyre Therapeutics, Inc. to report earnings per share of -0.12 for Q3 26, against a range of -0.13 to -0.11. The most recent reported quarter, Q2 26, came in at -0.12, a 100.0% miss against the -0.06 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.01 | 0.00 | 0.00 | 0.00 | 0.03 | -0.02 | -0.10 | -0.12 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | - | 0.04 | 0.03 | 0.03 | 0.05 | 0.06 | -0.06 | -0.06 | -0.11 | -0.12 | -0.06 | -0.07 | -0.05 | -0.05 | 0.41 | 0.48 | ||||||||||
| Low Estimate | - | 0.04 | 0.03 | 0.03 | 0.05 | 0.06 | -0.08 | -0.06 | -0.13 | -0.14 | -0.06 | -0.07 | -0.05 | -0.05 | 0.35 | 0.40 | ||||||||||
| Consensus Estimate | - | 0.04 | 0.03 | 0.03 | 0.05 | 0.06 | -0.07 | -0.06 | -0.12 | -0.13 | -0.06 | -0.07 | -0.05 | -0.05 | 0.38 | 0.44 |
Pull Wall Street consensus for Gyre Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=GYRE&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "GYRE", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=GYRE&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();